文献速递细菌感染、耐药与抗菌药物

研究者发起的随机对照试验:新型抗菌药物注册试验的更高成本效益

Investigator-initiated Randomized Controlled Trials in Infectious Diseases: Better Value for Money for Registration Trials of New Antimicrobials.
PubMed 文献 · Clin Infect Dis · 2021-01-01

本观点文章对比了工业界主导与研究者发起的随机对照试验在目标、方法和成本上的差异,质疑当前注册试验成本的合理性。文章指出合同研究组织缺乏提高效率和降低成本的动力,建议临床试验网络在试验设计中发挥更大作用并主导基于风险的自适应监查。

要点

  • 工业界注册试验成本高,研究者发起的试验可低成本招募多重耐药菌感染患者。
  • 合同研究组织缺乏降低试验成本的动力,全面监查所有试验数据的价值存疑。
  • 建议临床试验网络主导基于风险的自适应监查,与工业界合作优化招募并降低成本。

核心结论

  • 研究者发起的试验可能为新型抗菌药物注册提供更高成本效益,当前注册试验成本合理性存疑。

研究设计与样本

  • 观点文章,对比工业界主导与研究者发起的随机对照试验的目标、方法和成本。

主要发现

  • 研究者发起的试验已成功招募多重耐药菌所致严重感染患者且成本较低。
  • 合同研究组织以显著成本提供监查,缺乏提高试验效率或降低成本的动力。
  • 全面监查所有试验数据的价值存疑。

临床怎么用

  • 临床试验网络应在随机对照试验设计和规划中发挥更大影响。
  • 临床试验网络应主导基于风险的自适应监查。
  • 临床试验网络应与工业界合作优化招募效率并降低注册试验成本。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Randomized controlled trials (RCTs) conducted by the industry are expensive, especially trials conducted for registration of new drugs for multidrug-resistant (MDR) bacteria. Lower-cost investigator-initiated trials have recently been successful in recruiting patients with severe infections caused by MDR bacteria. In this viewpoint, we contrast the aims, methods, and resulting costs of industry-led and investigator-initiated trials and ask whether contemporary registration trial costs are justified. Contract research organizations, delivering and monitoring industry-sponsored trials at a significant cost, have little incentive to make trials more efficient or less expensive. The value of universal monitoring of all trial data is questionable. We propose that clinical trial networks play a more influential role in RCT design and planning, lead adaptive risk-based trial monitoring, and work with the industry to maximize efficient recruitment and lower costs in registration trials for the approval of new antimicrobials.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Paul M, Harbarth S, Huttner A, et al. Investigator-initiated Randomized Controlled Trials in Infectious Diseases: Better Value for Money for Registration Trials of New Antimicrobials. Clin Infect Dis. 2021. PMID: 32619238. doi:10.1093/cid/ciaa930

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。